MTOR and metabolic dysfunction-associated steatotic liver disease: The overdose of APAP reduces LC3-II and Beclin1 levels through the AMPK/mTOR/SREBP-1c pathway, inhibiting autophagy and exacerbating the progression of NAFLD.